<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561025</url>
  </required_header>
  <id_info>
    <org_study_id>2016/883</org_study_id>
    <secondary_id>2017-000331-14</secondary_id>
    <nct_id>NCT03561025</nct_id>
  </id_info>
  <brief_title>Diagnostic Potential of PET/MRI in Cardiac Sarcoidosis</brief_title>
  <official_title>Diagnostic Potential of PET/MRI in Cardiac Sarcoidosis: A Pilot Study Combining Advanced MRI and 18F-FDG and 18F-GE180 PET of the Myocardium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Olavs Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to find better and more specific non-invasive methods to diagnose and
      stage cardiac sarcoidosis with the use of advanced imaging modalities, simultaneous 3T MRI
      and PET. Cardiac sarcoidosis is a disease of possibly fatal outcome in young people. The use
      of a combined PET/MRI system with 18F-FDG and a new inflammation-tracer (18F-GE180) can
      become a future game changer.

      Sarcoid induced focal inflammation in myocardium should show high 18F-GE180 uptake. 18F-GE180
      PET scans will give reliable data about inflammatory sarcoidosis activity in the myocardium.
      18F-GE180 PET is expected to improve diagnostic accuracy compared to 18F-FDG-PET and/or
      contrast enhanced MRI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnostic accuracy of a combined 18F-FDG and 18F-GE-180 PET/MRI examination for diagnosing cardiac sarcoidosis</measure>
    <time_frame>One day after the test</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>18F-FDG-PET/MRI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-GE180-PET/MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-FDG-PET/MRI</intervention_name>
    <description>Contrast-enhanced MRI scanning after injection of 18F-FDG</description>
    <arm_group_label>18F-FDG-PET/MRI</arm_group_label>
    <arm_group_label>18F-GE180-PET/MRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>18F-GE180-PET/MRI</intervention_name>
    <description>Contrast-enhanced MRI scanning after injection of 18F-GE180</description>
    <arm_group_label>18F-FDG-PET/MRI</arm_group_label>
    <arm_group_label>18F-GE180-PET/MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart department: Suspicion of myocardial sarcoidosis after contrast enhanced cardiac
             MRI

          -  Lung department: Clinically verified lung and/or mediastinal sarcoidosis

        Exclusion Criteria:

          -  Known malignancies

          -  Treatment for sarcoidosis started

          -  Severe arrhythmia

          -  Patients with pacemakers or defibrillator

          -  Claustrophobia

          -  Known alcohol or drug abuse

          -  Kidney failure (eGFR &lt; 30)

          -  Weight &gt; 120 kg

          -  Diabetes Mellitus type I and II

          -  Patients that take immunosuppressive or immunomodulatory medication for any reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund Søvik</last_name>
    <role>Study Chair</role>
    <affiliation>St. Olavs Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Knut Haakon Stensaeth, md, phd</last_name>
    <phone>+47 97533346</phone>
    <email>knut.haakon.stenseth@stolav.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Live Eikenes, phd</last_name>
    <phone>+47 99568081</phone>
    <email>live.eikenes@ntnu.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Olav University Hospital, Dept Radiology and Nuclear Medicine</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knut Haakon Stensæth, md phd</last_name>
      <phone>+47 97533346</phone>
      <email>knutsten@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 6, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnostic Imaging</keyword>
  <keyword>Positron Emission Tomography Computed Tomography</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

